Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21152067 | 0.91 | POLB (0.47) | ALDH1A1POLBKDRTSHRSMN1; SMN2 | |
| SCHEMBL24974634 | 0.85 | POLB (0.56) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL24974782 | 0.82 | MAPT (0.58) | ALDH1A1POLBTSHRSMN1; SMN2USP2 | |
| SCHEMBL24974592 | 0.82 | ALDH1A1 (0.46) | ALDH1A1POLBKDRTSHRSMN1; SMN2 | |
| SCHEMBL24974742 | 0.80 | MAPT (0.58) | ALDH1A1POLB | |
| SCHEMBL24974540 | 0.78 | PKM (0.47) | KDR | |
| SCHEMBL24974573 | 0.77 | HDAC1 (0.42) | ALDH1A1POLBKDRTSHRUSP2 | |
| SCHEMBL24974737 | 0.77 | HDAC1 (0.42) | ALDH1A1POLBKDRTSHRUSP2 | |
| SCHEMBL24974601 | 0.76 | ROCK2 (0.54) | ALDH1A1POLBTSHRL3MBTL1 | |
| SCHEMBL24974639 | 0.76 | SMN1; SMN2 (0.41) | ALDH1A1TSHRSMN1; SMN2USP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 1203/4885POLB 4058/4885KDR 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.